1. Scrip
  2. >>Leadership
  3. >>Executives On The Move

Appointments: News From GSK, DBV Technologies, Complexa, Synlogic And Motif Bio

 
• By Alexandra Shimmings

This week’s announcements include the retirement of GlaxoSmithKline’s CFO, new CEOs at Complexa, Synlogic and Horizon Discovery, and other new hires at TP Therapeutics and Motif Bio, and a new board member at DBV Technologies.

GlaxoSmithKline PLC's chief financial officer Simon Dingemans has informed the board of his intention to retire and to step down from the board in May 2019. The board will now conduct a global search both internally and externally to identify a successor. Dingemans joined GSK in 2011 and, as CFO, has led finance and a number of other group functions, including technology and IT, real estate and procurement. GSK noted that, as a voluntary leaver, Dingemans would not receive any severance payment when he leaves the company.

Complexa Inc., a clinical-stage biopharmaceutical company, has appointed Francisco Salva as its president and CEO, effective immediately. Most recently, Salva was a founder and vice president of operations for Acerta Pharma BV, culminating in a $4bn investment by AstraZeneca PLC for a controlling ownership interest

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Executives On The Move

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.

Executives On The Move: Ten CMOs And Three CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.

Executives On The Move: Six CMOs, Five CEOs And Two CSOs Among This Week’s Changes

Recent moves in the industry include C-suite changes at Merck KGaA, Newleos Therapeutics and Artiva Biotherapeutics, plus Valo Therapeutics acquires chief executive officer from Johnson & Johnson.

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

More from Leadership

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.